Table 3.
Univariate Cox analysis of the correlation between clinicopathological parameters and progression-free/overall survival of breast cancer patients
| Variables | PFS
|
OS
|
||
|---|---|---|---|---|
| HR (95% CI) | P-value | HR (95% CI) | P-value | |
|
| ||||
| Age (years) | ||||
| <40 vs ≥40 | 1.805 (1.044–3.121) | 0.034 | 2.050 (1.092–3.848) | 0.025 |
| Tumor stage | ||||
| I and II vs III | 1.692 (0.976–2.935) | 0.061 | 1.465 (0.769–2.792) | 0.245 |
| Lymph node status | ||||
| Positive vs negative | 0.764 (0.452–1.290) | 0.313 | 0.944 (0.521–1.711) | 0.850 |
| Tumor size | ||||
| <5 cm vs ≥5 cm | 0.476 (0.240–0.943) | 0.033 | 0.493 (0.229–1.062) | 0.071 |
| Molecular subtypes | ||||
| Luminal and HER2+ vs triple negative | 1.264 (0.572–2.791) | 0.563 | 0.939 (0.417–2.110) | 0.878 |
| ER | ||||
| Positive vs negative | 1.162 (0.685–1.971) | 0.579 | 1.114 (0.600–2.068) | 0.732 |
| PR | ||||
| Positive vs negative | 1.469 (0.887–2.431) | 0.135 | 1.403 (0.782–2.518) | 0.257 |
| HER2 | ||||
| Positive vs negative | 0.735 (0.433–1.246) | 0.253 | 0.737 (0.396–1.371) | 0.335 |
| Ki67 | ||||
| ≤30% vs >30% | 0.980 (0.583–1.646) | 0.939 | 0.725 (0.389–1.349) | 0.309 |
| PIK3CA mutational status | ||||
| PIK3CA mutation vs wild-type | 1.257 (0.732–2.160) | 0.407 | 1.946 (0.987–3.837) | 0.055 |
| Exon 9 mutation vs wild-type | 0.794 (0.389–1.621) | 0.527 | 1.444 (0.515–4.050) | 0.485 |
| Exon 20 mutation vs wild-type | 1.696 (0.883–3.259) | 0.113 | 1.950 (0.907–4.194) | 0.087 |
| p.542/545 mutation vs wild-type | 0.731 (0.346–1.547) | 0.413 | 1.646 (0.508–5.329) | 0.406 |
| p.1047 mutation vs wild-type | 1.662 (0.819–3.371) | 0.159 | 2.2025 (0.857–4.783) | 0.108 |
Note: P<0.05 was considered statistically significant and those values are shown in bold.
Abbreviations: ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; OS, overall survival; PFS, progression-free survival; PR, progesterone receptor.